4030W92

Drug Profile

4030W92

Alternative Names: GR 403W92

Latest Information Update: 16 Jul 1999

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Analgesics
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 16 Jul 1999 Discontinued-II for Neuropathic pain in United Kingdom (PO)
  • 07 Jul 1999 No-Development-Reported for Neuropathic pain in United Kingdom (PO)
  • 07 Jul 1999 Profile reviewed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top